Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide

The DMV Region and Psychedelic Therapy: A Policy Snapshot

The Washington DC, Maryland, and Virginia corridor sits at an unusual intersection. It is home to a politically engaged, educated population, large numbers of federal workers and veterans, and a policy environment that is both closely watched and uniquely constrained. What happens here, particularly in DC itself, often signals what is coming nationally.

For people in this region exploring psychedelic therapy in 2026, the picture is clearer than it was two years ago, though it is still far from simple. Ketamine is the only widely available, legally unambiguous option across all three jurisdictions. Psilocybin remains a Schedule I substance under federal law. And because DC sits within federal jurisdiction, that distinction matters more here than almost anywhere else in the country.

For a broader overview of how federal law shapes access across the United States, see our post Is Psychedelic Therapy Legal in the United States?

Washington DC: Decriminalization Without a Therapeutic Framework

Washington DC voters passed Initiative 81 in November 2020 with 76% support, making the cultivation, possession, and non-commercial distribution of entheogenic plants and fungi among the Metropolitan Police Department’s lowest law enforcement priorities. Psilocybin mushrooms, ayahuasca, ibogaine, and mescaline-containing cacti are all covered under the measure.

What that means in practice: DC police are directed to treat entheogenic plant possession as their lowest enforcement priority for adults 18 and older. The initiative also calls on the District’s attorney general and the U.S. Attorney for DC to cease prosecution of residents for these activities.

What it does not mean: psilocybin is not legal in DC. There is no licensed therapeutic access program, no regulated service center model, and no legal pathway to purchase psilocybin. The District’s unique status as a federal territory means that congressional jurisdiction applies, adding a layer of complexity that pure state-level reform cannot fully resolve.

For people working in federal employment, holding security clearances, or in other roles where legal exposure matters, this distinction is significant. Deprioritized enforcement is not the same as legal protection, and it would be misleading to suggest otherwise.

Ketamine therapy, by contrast, is available and clearly legal in DC. Multiple psychiatrist-led and anesthesiology-led clinics operate within the District, offering both intravenous ketamine infusions and FDA-approved esketamine (Spravato) nasal spray for treatment-resistant depression. These are evidence-based, supervised clinical settings, and they are the most accessible professionally supported option for DC residents today.

Maryland: Legislation in Progress, Ketamine Available Now

Maryland does not have a psilocybin decriminalization measure in place, and psilocybin remains a Schedule I controlled substance under Maryland Criminal Law. No city or county in the state has passed a deprioritization resolution.

That said, Maryland has been one of the more active states on the policy side. The state established a Psychedelic Substances Task Force in 2023, which released its report in January 2024 recommending a regulated psilocybin access program modeled on Oregon’s Measure 109 framework. HB 0160, introduced in the 2025 legislative session, would implement that recommendation by creating a licensed therapeutic access program administered by the Maryland Department of Health. As of 2026, the bill has not passed into law.

Maryland also created a state fund in 2022 for psychedelic-assisted therapy research specifically targeting veterans, covering psilocybin, MDMA, and ketamine for PTSD and related conditions. This reflects genuine legislative interest in the evidence base, even where broad access remains out of reach.

For Maryland residents right now, ketamine therapy is the practical entry point. Clinics are well established across the Baltimore-Washington corridor, including in the Bethesda area. This is where the therapeutic infrastructure is most developed, and it is where professionally supported care is most accessible under current law.

Virginia: A Conditional Path Forward

Virginia’s legislative history on psychedelics is worth understanding carefully, because the state has taken a meaningfully different approach than most.

In April 2026, Virginia’s governor signed two bills that create a conditional framework for psilocybin access: if and when the FDA formally approves a psilocybin formulation and rescheduling follows at the federal level, Virginia would automatically move to regulate therapeutic access at the state level. This is a policy mechanism designed to position Virginia ahead of anticipated federal action rather than waiting for a separate legislative cycle.

A separate bill, SB 1101, which was passed unanimously by the Virginia Senate in early 2025, established an advisory council on breakthrough therapies for veteran suicide prevention, with a report due to the governor and legislature by December 2026. Psilocybin and MDMA are among the FDA-designated breakthrough therapies covered under that measure.

In practical terms, this means Virginia is waiting on federal movement rather than building an independent access program. Psilocybin-assisted therapy is not available through any licensed program in Virginia as of 2026.

Ketamine therapy is the exception. Virginia has an established network of licensed ketamine clinics, particularly in Northern Virginia and the Hampton Roads area. For veterans specifically, some clinics in the region operate under VA Community Care Agreements, which can allow VA-covered referrals for ketamine infusion therapy. This is a significant and underused option for the large active-duty and veteran population in the state.

What Ketamine Therapy Actually Involves

Because ketamine is the clearest and most available option across DC, Maryland, and Virginia, it is worth being direct about what the treatment involves and what the evidence shows.

Ketamine is an anesthetic that, at sub-anesthetic doses, affects the glutamate system in ways that can produce rapid antidepressant effects. It is not a classic serotonergic psychedelic like psilocybin, but it does produce altered states of consciousness, typically described as dissociative, during infusion. The experiences are shorter, usually 45 to 60 minutes per infusion, and the therapeutic context varies significantly by clinic.

Intravenous ketamine is administered off-label for depression, anxiety, PTSD, and chronic pain. Esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression and is administered as a nasal spray in a monitored clinical setting, with insurance coverage increasingly available for qualifying patients.

The research base is meaningful but still developing. Studies show rapid and sometimes significant reductions in depressive symptoms, particularly for treatment-resistant cases. The durability of effects varies, and most protocols involve an initial series of infusions followed by maintenance sessions. Integration support, meaning psychological work done before and after the experience, appears to improve outcomes, though it is not universally offered by ketamine providers.

This is where working with a concierge service rather than navigating a clinic directory on your own can make a genuine difference in the quality of care you receive.

What to Do Right Now

If you are in the DMV region and seriously considering psychedelic therapy, here is how to think about your options clearly.

Ketamine is available today across DC, Maryland, and Virginia in licensed clinical settings. It is the only professionally supervised, legally clear psychedelic therapy option in the region, and for many people with treatment-resistant depression, anxiety, or PTSD, it is a legitimate and evidence-supported path.

Psilocybin is not legally available through any therapeutic program in this region as of 2026. DC’s Initiative 81 deprioritizes enforcement, but it does not create a safe or regulated access framework. Maryland and Virginia are tracking federal developments, but no program is operational.

Finding quality ketamine care in the DMV is not straightforward. Clinic quality, protocols, and integration support vary considerably. This is exactly the kind of navigation where a concierge approach, one that matches you with screened providers based on your specific situation, can protect you from making a poorly informed choice in a high-stakes context.

JourneyŌM works with seekers across the region to clarify what is actually available, assess readiness, and connect them with vetted professional guides and clinical providers. If you are unsure where to start or want a clear-eyed conversation about your options before committing to anything, that is where we can help.